Erbitux misses in Mayo colon cancer study

Researchers at the Mayo Clinic and colleagues reported that Erbitux cetuximab plus FOLFOX chemotherapy missed the primary endpoint of significantly improving disease-free survival at 3 years vs. FOLFO...